Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index; 11 of the 23 sources its claims cite were checked for support.

Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK

Open access

Abstract

Background: UK studies examining vitiligo burden and vitiligo-related healthcare resource utilization (HCRU) are lacking. Objective: To describe the incidence and prevalence of vitiligo, the demographic and clinical characteristics of patients with vitiligo, vitiligo burden, HCRU, incidence of mental health comorbidities and management strategies, including treatment patterns. Methods: This retrospective study used UK Clinical Practice Research Datalink and Hospital Episode Statistics databases to analyse patients with vitiligo from 1 January 2010 to 31 December 2021. Results: Among 17 239 incident patients, mean incidence of vitiligo was 0.16 (2010-2021) per 1000 person-years [PY; range 0.10 (2020-COVID-19) to 0.19 (2010/2013/2018)]; among 66 217 prevalent patients, prevalence increased from 0.21% (2010) to 0.38% (2021). The most common comorbidities recorded after vitiligo diagnosis were diabetes (19.4%), eczema (8.9%), thyroid disease (7.5%) and rheumatoid arthritis (6.9%). Mental health diagnoses recorded at any time included depression and/or anxiety (24.6%), depression (18.5%), anxiety (16.0%) and sleep disturbance (12.7%), and recorded after vitiligo diagnosis in 6.4%, 4.4%, 5.5% and 3.9%, respectively. Mental health comorbidities were more common in White (e.g. depression and/or anxiety 29.0%) than in Black (18.8%) and Asian (16.1%) patients. In adolescents, depression and/or anxiety was most commonly diagnosed after a vitiligo diagnosis than before (7.4% vs. 1.8%). Healthcare resources were used most frequently in the first year after vitiligo diagnosis (incident cohort), typically dermatology-related outpatient appointments (101.9/100 PY) and general practitioner consultations (97.9/100 PY). In the year after diagnosis, 60.8% of incident patients did not receive vitiligo-related treatment (i.e. topical corticosteroids, topical calcineurin inhibitors, oral corticosteroids or phototherapy), increasing to 82.0% the next year; median time from diagnosis to first treatment was 34.0 months (95% confidence interval 31.6-36.4). Antidepressants and/or anxiolytics were recorded for 16.7% of incident patients in the year after diagnosis. In 2019, 85.0% of prevalent patients did not receive vitiligo-related treatments. Conclusion: Most patients were not on vitiligo-related treatments within a year of diagnosis, with the time to first treatment exceeding 2 years, suggesting that vitiligo may be dismissed as unimportant. New effective treatments, early initiation and psychological intervention and support are needed to reduce the vitiligo burden on patients. © 2024 The Author(s).

Overview

CoChat Summary

TL;DR

In a UK retrospective study using CPRD and HES data, mean vitiligo incidence was 0.16 per 1000 person-years from 2010–2021 and prevalence rose from 0.21% in 2010 to 0.38% in 2021. Most patients received no vitiligo-related treatment within a year of diagnosis, and median time to first treatment was 34.0 months.

Key findings

  • Among 17,239 incident patients, mean incidence was 0.16 per 1000 person-years [range 0.10 (2020) to 0.19 (2010/2013/2018)]; among 66,217 prevalent patients, prevalence increased from 0.21% (2010) to 0.38% (2021).
  • Comorbidities recorded after vitiligo diagnosis included diabetes (19.4%), eczema (8.9%), thyroid disease (7.5%) and rheumatoid arthritis (6.9%). Mental health diagnoses at any time included depression and/or anxiety (24.6%), depression (18.5%), anxiety (16.0%) and sleep disturbance (12.7%); recorded after vitiligo diagnosis in 6.4%, 4.4%, 5.5% and 3.9%, respectively. Depression and/or anxiety was more common in White patients (29.0%) than Black (18.8%) or Asian (16.1%) patients; in adolescents it was more commonly diagnosed after than before vitiligo (7.4% vs. 1.8%).
  • Healthcare resource use was highest in the first year after diagnosis: dermatology-related outpatient appointments 101.9/100PY and GP consultations 97.9/100PY. In the first year after diagnosis, 60.8% of incident patients had no vitiligo-related treatment, increasing to ≥82.0% from the second year onward; median time from diagnosis to first treatment was 34.0 months (95% CI 31.6–36.4). In 2019, 85.0% of prevalent patients had no vitiligo-related treatment.
  • Antidepressants and/or anxiolytics were recorded for 16.7% of incident patients in the year after diagnosis.

Methods

  • Retrospective longitudinal study using UK Clinical Practice Research Datalink (CPRD Aurum) linked to Hospital Episode Statistics (HES), 1 January 2010 to 31 December 2021. The incident cohort included 17,239 patients aged ≥12 years with a first vitiligo diagnosis in 2010–2019; the prevalent cohort included 66,217 patients aged ≥12 years with a pre-existing diagnosis on 1 January of any year 2010–2021.
  • Annual incidence was calculated per 1000 person-years and point prevalence on 1 January each year. Demographics and comorbidities were described for incident cases in the 5 years before and after diagnosis; HCRU was reported per 100 person-years; treatment patterns were identified from prescription/treatment records, including time to first, second and third vitiligo-related treatments.
  • Treatment-pattern Sankey analysis included incident patients in the HES outpatient database diagnosed no later than 31 December 2018; a treatment gap was defined as 18 months without any treatment record. All analyses were descriptive.

Limitations

  • The paper states that data did not contain prescription fulfilment, over-the-counter treatments, or private dermatologist appointments/prescriptions; hospital dermatologist treatment records were available only if continued by a GP; phototherapy capture in CPRD Aurum and HES outpatient databases may have been limited, potentially underestimating phototherapy utilization. The study lacked a control group, did not include patients aged <12 years, lacked vitiligo-specific extent measures and patient-reported outcomes/QoL such as VitiQoL, and diagnoses may have been made by GPs rather than dermatologists.
  • Evident from the text: missing data were substantial for BMI (11,375 missing) and smoking status (9,651 missing), which the authors note hinders definitive conclusions on smoking. The descriptive observational design cannot establish causality.
  • The authors also note possible under-representation of mental health diagnoses in Black and minority ethnic populations due to inequalities, barriers to accessing mental health services, and cultural stigma.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/bjd/ljae133

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 (a) Incidence and (b) prevalence of vitiligo. CI, confidence interval; PY, person-years.
Figure 1 (a) Incidence and (b) prevalence of vitiligo. CI, confidence interval; PY, person-years.CC-BY · From the PDF
Figure 2 Comorbidities in the incident cohort following a diagnosis of vitiligo. AMD, age-related macular degeneration. a Other dermatological comorbidities included alopecia areata and lichen planus; b other comorbidities included myasthenia gravis, pernicious anaemia, systemic lupus erythematosus, Guillain-Barré syndrome, Sjögren syndrome and Addison disease.
Figure 2 Comorbidities in the incident cohort following a diagnosis of vitiligo. AMD, age-related macular degeneration. a Other dermatological comorbidities included alopecia areata and lichen planus; b other comorbidities included myasthenia gravis, pernicious anaemia, systemic lupus erythematosus, Guillain-Barré syndrome, Sjögren syndrome and Addison disease.CC-BY · From the PDF
Figure 3 Vitiligo-related treatment/management strategy use in (a) the 5 years after a vitiligo diagnosis in the incident cohort and (b) calendar years 2010 and 2019 in prevalent patients (follow-up in the relevant year). Red box and associated numbers denote the percentage of patients not on any vitiligo-related treatments. a No vitiligo-related or non-vitiligo-related treatments or management strategies. b Non-vitiligo-related treatment/ management strategies included psychological management strategies (i.e. antidepressants and/or anxiolytics and psychological referrals) and adjuvant management strategies (i.e. camouflage prescription, sunscreen, vitamin D, camouflage referrals and dermatology referrals). c Vitiligo-related treatments/management strategies included topical corticosteroids, topical calcineurin inhibitors, oral corticosteroids and light and laser therapy.
Figure 3 Vitiligo-related treatment/management strategy use in (a) the 5 years after a vitiligo diagnosis in the incident cohort and (b) calendar years 2010 and 2019 in prevalent patients (follow-up in the relevant year). Red box and associated numbers denote the percentage of patients not on any vitiligo-related treatments. a No vitiligo-related or non-vitiligo-related treatments or management strategies. b Non-vitiligo-related treatment/ management strategies included psychological management strategies (i.e. antidepressants and/or anxiolytics and psychological referrals) and adjuvant management strategies (i.e. camouflage prescription, sunscreen, vitamin D, camouflage referrals and dermatology referrals). c Vitiligo-related treatments/management strategies included topical corticosteroids, topical calcineurin inhibitors, oral corticosteroids and light and laser therapy.CC-BY · From the PDF

Verification

Claims the paper makes

5 Valid · 1 Not valid · 7 Not checked · 57 Own results and interpretations

28 more claims

Create a free account to see all 70 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 30
  • It may state two separate claims as one. 10

Create a free account to see these claims.

Citations

Cites

Show all 22 references

Cited by

See all 21

Metadata

Authors
Eleftheriadou, V., Delattre, C., Chetty-Mhlanga, S., Lee, C., Girardat-Rotar, L., Khan, I., Mathew, A., & Thompson, A. R.
Affiliations
  • The Royal Wolverhampton NHS Trust (GB)
  • Incyte Biosciences International , Morges , Switzerland
  • IQVIA Real World Solutions , Basel , Switzerland
  • IQVIA (United Kingdom) (GB)
  • University of Warwick (GB)
  • Incyte Biosciences UK Ltd , Leatherhead , UK
  • Cardiff and Vale University Health Board (GB)
Corresponding author
Eleftheriadou, Viktoria
Venue
British Journal of Dermatology
Published
2024-03-27
Volume
191
Issue
2
Pages
216-224
ISSN
  • 0007-0963 (ISSN-L)
  • 1365-2133
OpenAlex
W4393220563
Cited by
21
References
22
Citations by year
2026: 9 · 2025: 7 · 2024: 5
FWCI
4.70
Type
journal article
Language
en
Open access
Locations
  • British Journal of Dermatology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
Funders
Incyte Corporation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › melanin and skin pigmentation
  • Health Sciences › Medicine › Dermatology › Dermatologic Treatments and Research
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
vitiligo, disease burden, healthcare resource utilization, incidence and prevalence, psychiatric comorbidity, anxiety and depression, sleep disorders, treatment patterns, topical corticosteroids, topical calcineurin inhibitors, phototherapy, systemic therapy, health care access disparities, adolescents, ethnic disparities, diabetes comorbidity, atopic dermatitis, thyroid dysfunction, rheumatoid arthritis
MeSH terms
Adolescent, Adult, Aged, Child, Child, Preschool, Female, United Kingdom, Humans, Infant, Longitudinal Studies, Male, Middle Aged, Patient Acceptance of Health Care, Retrospective Studies, Vitiligo, Comorbidity, Incidence, Prevalence, Cost of Illness, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK. https://app.cochat.ai/papers/10.1093/bjd/ljae133
The paper
Eleftheriadou, V., Delattre, C., Chetty-Mhlanga, S., Lee, C., Girardat-Rotar, L., Khan, I., Mathew, A., & Thompson, A. R. (2024). Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae133

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.